The most promising solution for Alzheimer/Parkinson's diseases


Amyloid plaques are no longer regarded as the pathogenic forms of Alzheimer's beta amyloid peptide (Abeta). Instead, small oligomers of amyloid proteins (Abeta and alpha-synuclein) that form Ca2+ permeable  channels (amyloid pores) are now  considered as the most neurotoxic species of amyloid proteins in neurodegenerative disorders. By disrupting Ca2+ homeostasis in brain cells, amyloid oligomers induce dramatic synaptic dysfunctions, impaired plasticity and neuronal degeneration. Hence, the oligomer  model has all but supplanted the classical amyloid cascade.


Our group demonstrated that amyloid pores are formed by a common mecanism that can be summarized in three steps: 1- binding of the amyloid protein to the plasma membrane of a brain cell through a primary interaction with a ganglioside (GM1 or GM3) followed by 2- cholesterol-assisted insertion and 3- oligomerization into a Ca2+ permeable pore (Di Scala et al., Sci Rep. 2016, 6: 28781).


Elucidating this universal mechanism allowed us to create the first inhibitor of amyloid pore formation, now called AmyP53, that is active against wild-type and mutant forms of the proteins involved in Alzheimer's and Parkinson's diseases. A full description of the anti-pore properties of this inhibitor has been published here. 


Disruptive technology

AmyP53 is not only one of the first molecules that target the oligomer cascade, it is the only one that  can block the formation of the neurotoxic oligomers in the plasma membrane of brain cells.



AmyP53 now tested in animals by AmyPore!


MTD and DRF studies in male and female rats


No toxicity at 80 mg/kg by intravenous administration


No toxicity at 5 mg/kg by nasal administration


Now ready for nasal spray formulation!


Our work on the molecular organization of lipid rafts quoted in Wikipedia

(ref. 8 here)


J. Fantini H-index: 56

Not far from 10000 citations



10000 visitors milestone reached!


L3 PGF Students


UE Option 2020
Ateliers de Physiopathologie TD n°1.pdf
Document Adobe Acrobat 553.7 KB
UE Diabètes 2020
UE Diabètes TD Fev 2020.pdf
Document Adobe Acrobat 205.6 KB
UE Diabètes 2020
Schéma métabolisme Foie.JPG
Image JPG 96.1 KB
UE Diabètes 2020
Régulations hormonales.JPG
Image JPG 46.3 KB
UE La Biologie en Marche 2020
Actualités scientifiques 05/02/2020
Retrovirus & Coronavirus.pdf
Document Adobe Acrobat 4.9 MB
UE Diabètes 2020
TD UE Diabètes Correction 1.pdf
Document Adobe Acrobat 70.0 KB
UE BioMembranes 2020
Pour les étudiants de L2
Cours & TD 2020.pdf
Document Adobe Acrobat 682.1 KB
UE La Biologie en Marche
Diaporama Mutations et résistance virus.
Document Adobe Acrobat 1.1 MB
UE Ateliers de Physiopathologie
Séance de TD du 20/02/2020
Correction TD Ateliers de Physio-Patholo
Document Adobe Acrobat 850.4 KB
UE BioMembranes
Séance de TD n°1
Correction 1 BioMembranes.pdf
Document Adobe Acrobat 204.7 KB



GalCer Molecule of the Month

February 2005

15 years anniversary !!!!

If you want to learn how to draw a sphingolipid molecule, this is the place to go!


Done in Marseille!

Spectacular vesicles obtained under prebiotic conditions by Juliette Aubé, currently undergradutate student in Biology at Aix-Marseille University (Origin of Life and Molecular Evolution Course): a simple mixture of nonanoic acid, nonanol and water... and that's it!


My 4th PNAS article just published:


Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B.


Still another ganglioside story!


In this research I did the molecular modeling studies. Here is a sample:


Two other samples (Syt2-GT1b complex):




The J. Fantini personal page has been created in September 2017


LinkedIn profile